See how Diana DeGette's votes line up with your values.
DeepSyte scores Diana DeGette's record on the issues you care about — not party, not press releases. Take the 2-minute values quiz to see your personal alignment.
Sign in and take the values quiz to see how Diana DeGette's votes line up with your views.
Prediction track record
How often we called Diana DeGette's passage votes correctly, from their stated positions on each bill's tagged topics. Excludes “unclear” calls and abstentions.
A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress.
To prohibit the disclosure of records by the Secretary of Housing and Urban Development of individuals for the purposes of immigration enforcement, and for other purposes.
A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress.
Based on 1 data point across public statements and recorded votes · AI analysis of public records
118-hr-6918·Consistent
Supporting Pregnant and Parenting Women and Families Act
92/100
What they said
May 5, 2026
Rep. DeGette and over 250 Congressional Democrats argue that the FDA's authority to regulate medication abortion should be upheld, that mifepristone has been proven safe and effective, and that courts should not override FDA determinations on drug safety and efficacy.
Rep. DeGette's statement defends FDA authority to regulate medication abortion and opposes restrictions on mifepristone access. The bill restricts federal oversight of state TANF spending on pregnancy centers that discourage abortion and promote childbirth. DeGette's NO vote aligns with her stated position: she opposes barriers to abortion access and supports FDA/federal authority over drug safety, while this bill shields state funding for anti-abortion pregnancy centers from federal reasonableness review. The votes point in the same direction on the underlying question of abortion access and federal regulatory authority.
Pairs with ambiguous language and high uncertainty are withheld until more data is available. Procedural, cloture, and amendment votes are excluded — they don't cleanly signal substantive support or opposition.
Pro analysis
AI rep analysis — Pro
Get an AI-narrated read on Diana DeGette's full voting record against your stated values — aligned themes, conflicts, notable votes, and what to watch for.
We haven't extracted campaign positions for Diana DeGette yet. Once their campaign website or position pages are processed, this card will track what they said vs how they voted.
Crossing the aisle
Passage votes where Diana DeGette broke ranks with ≥75% of Democrats. Threshold catches substantively partisan splits; unanimous-ish or close votes are excluded.
1
Cross-aisle vote
118-hr-2670·Dec 14, 2023·78% of D voted YES
National Defense Authorization Act for Fiscal Year 2024
DeGette, Matsui, Beyer Statement on Illegal Impoundment of Health Research Funds
Position: The representatives state that the administration illegally impounded $78 million in FY2025 AHRQ health research funding, in violation of the Impoundment Control Act and Article I, and call on Republicans to join in upholding Congress's power of the purse.
WASHINGTON, D.C. — Today, Representatives Diana DeGette (CO-01), Doris Matsui (CA-07), and Don Beyer (VA-08) released the following statement after the Government Accountability Office (GAO) issued a legal determination confirming the administration illegally impounded $78 million in Fiscal Year 2025 funding for the Agency for Healthcare Research and Quality (AHRQ). The decision comes more than a year after Reps. DeGette, Matsui and Beyer sent the initial request for a nonpartisan legal opinion on the matter.
“The GAO’s decision today confirms what we have known for over a year: Donald Trump is stealing taxpayers’ dollars that Congress set aside to improve Americans’ health. The administration’s unilateral dismantling of the Agency for Healthcare Research and Quality’s grantmaking operations is an illegal impoundment of Congressionally appropriated funds.
“Under Article I of the Constitution, the power of the purse rests strictly with Congress, not the executive branch. Trump’s administration cannot simply refuse to spend the resources we authorized for lifesaving health care research. Republicans must join Democrats in demanding that the Constitution is upheld.”
Background:
The Trump administration’s massive cuts at the Department of Health and Human Services beginning April 1, 2025, disrupted grant funding for health care research across the country, including in Colorado. AHRQ suffered particularly devastating impacts to its grants supporting more efficient, effective, and safe health care. Grantmaking at AHRQ halted: from April 1 to September 5, 2025, AHRQ did not issue a single grant. The agency would typically issue up to 73 grants during a comparable time period.
In September 2025, Representatives DeGette, Matsui and Beyer sent a request to GAO for their legal opinion on whether disruptions of AHRQ’s grantmaking process represented illegal withholding of funds in violation of the Impoundment Control Act, which regulates the president’s ability to delay or withhold Congressionally appropriated spending. The GAO is often called the “Congressional watchdog” for its role in investigating federal government spending and performance.
Today, after a lengthy nonpartisan investigation, the GAO announced its findings that the Trump administration did illegally withhold—or impound—$78 million Congress directed to support healthcare research.
###
DeGette Delivers Bill to Cap Insulin Cost at $35 Per Month
Position: The release supports legislation capping the cost of insulin at $35 per month for insured individuals and introduces the bipartisan INSULIN Act to that end.
WASHINGTON, D.C. — Today, Representative Diana DeGette (CO-01), Co-Chair of the Congressional Diabetes Caucus, along with Representatives Mariannette Miller-Meeks (IA-01), Kim Schrier(WA-08), Rob Bresnahan (PA-08), and Angie Craig (MN-02), introduced the Improving Needed Safeguards for Users of Lifesaving Insulin Now (“INSULIN”) Act. This bill will cap the cost of insulin at $35 per month for insured individuals.
“Insulin insecurity is not a partisan issue. It’s a life-or-death issue,” said Rep. DeGette. “I have fought for years to lower the price of insulin for the over 40 million Americans living with diabetes. I have met with too many Coloradans who have shared their painful experience of rationing their insulin so they could afford groceries. No one in America should be forced to choose between their life-saving medication or feeding their families.”
"As a doctor, I have spent my career fighting for patients, and I've watched too many of them ration a hundred-year-old medicine because the price tag made it impossible to afford,” said Rep. Mariannette Miller-Meeks, M.D.. “That's not right, and it never should have taken this long to fix. I'm proud to lead this effort in the House, and I won't stop until every American with diabetes can afford the insulin that keeps them alive."
“As a doctor with Type 1 diabetes who depends on insulin, I understand the immediate need to bring down the cost of insulin – especially at a time when so many Americans are already struggling with high costs,” said Rep. Schrier. “I am proud to introduce this groundbreaking bipartisan legislation that will cap the price of insulin for all Americans and make a meaningful difference in the lives and the health of everyone in our districts.”
“Diabetes stole the lives of 100,000 Americans last year. Tens of millions of Americans are living with diabetes, and for many, insulin is a matter of life and death,” said Rep. Bresnahan. “No American should have to choose between paying the bills and getting the insulin they need, or risk their life rationing the doses they have left. This legislation isn’t just a Band-Aid on the problem. It delivers immediate relief for patients and reforms that will increase competition and drive down prices over the long term. Lowering the cost of insulin puts money back where it belongs: in the pockets of working families who need every dollar they earn. Middlemen and big corporations shouldn’t be making extra cash off the backs of working people who rely on insulin to survive.”
“Through the Inflation Reduction Act, we made great strides toward lowering the cost of prescription drugs by capping the cost of insulin for our nation’s seniors,” Rep. Craig said. “Now, it’s time to extend that benefit to all Americans. I’m proud to be joining my colleagues in introducing this critical bill that will ensure no Minnesotan has to choose between putting food on the table and picking up lifesaving medication.”
View the bill text here.
Background:
With more than 40.1 million Americans estimated to be living with diabetes, the INSULIN Act is the result of Rep. DeGette’s commitment to making health care affordable for more Americans.
The INSULIN Act will:
Cap out-of-pocket patient cost-sharing for individuals with insurance at $35 a month;
Prohibit health care plans from applying any deductible to select insulin products;
Help uninsured people with diabetes get access to insulin; and
Get biosimilar insulin to market more quickly.
As co-chair of the Congressional Diabetes Caucus, Rep. Diana DeGette has championed a multi-year, comprehensive effort to address the skyrocketing cost of insulin and improve care for millions of Americans living with diabetes, and she has worked to ensure people with diabetes have access to the latest standard of care in medicine and technology.
Before becoming the top Democrat on the Health subcommittee, Rep. DeGette launched the first-ever Congressional study to find legislative solutions for the worsening insulin pricing crisis.
Building on the study's framework, Rep. DeGette convened a historic Congressional hearing in April 2019. For the first time, all three U.S. insulin manufacturers and the nation's three largest pharmacy benefit managers (PBMs) were called to testify jointly about surging costs. Following nearly three hours of testimony, Rep. DeGette declared the current pricing system "fully broken" and issued a mandate to the executives to immediately develop collaborative cost-lowering solutions.
A similar bill has been introduced in the Senate by Senators Jeanne Shaheen (D-NH), Susan Collins (R-ME), Raphael Warnock (D-GA), and John Kennedy (R-LA).
This bill has broad support among diabetes advocates.
“The American Diabetes Association (ADA) appreciates and applauds the House’s bipartisan introduction of the INSULIN Act, which would limit out-of-pocket insulin costs for patients at $35 a month,” said Lisa Murdock, Chief Advocacy Officer of ADA. “A recent survey, commissioned by ADA, showed that 40% of insulin users currently pay $150 each month, and there is widespread bipartisan support across the U.S. for making insulin affordable. The INSULIN Act would ensure no one has to choose between paying for insulin and other necessities. This bill puts people first and is a commonsense way to lower health care costs for Americans depending on insulin to live.”
“For the millions of Americans who rely on insulin every day, no one should have to choose between paying for their medication and meeting other basic needs, said Dr. Robert Lash, Chief Medical Officer with the Endocrine Society. “The Endocrine Society applauds Representatives DeGette, Schrier, Miller-Meeks, Bresnahan, and Craig for introducing the INSULIN Act, which would help make insulin more affordable for people with private insurance while connecting uninsured patients to resources that can help them access this lifesaving medication. This bipartisan legislation is an important step toward ensuring that all people who need insulin can obtain it and stay healthy.”
“The Diabetes Leadership Council (DLC) and Diabetes Patient Advocacy Coalition (DPAC) applaud and thank Representatives DeGette, Miller-Meeks, Schrier, Bresnahan, and Craig for introducing the INSULIN Act of 2026,” said George Huntley, CEO. “This legislation will greatly improve access to affordable insulins for people living with diabetes, and it is time that the $35 monthly insulin co-pay cap apply to everyone as it does to Medicare beneficiaries today. We look forward to working to get this legislation across the finish line before the end of the 119th Congress.”
“For the more than 1.5 million Americans with type one diabetes (T1D), insulin access is life-or-death,” said Lynn Starr, Breakthrough T1D Chief Global Advocacy Officer. “By capping out-of-pocket cost at $35, the INSULIN Act ensures that people have dependable, affordable access to the insulin they require to live. We applaud Representatives DeGette, Miller-Meeks, Schrier, Bresnahan, and Craig for introducing the House INSULIN Act and urge their colleagues to stand with them on the side of all those living with T1D. While there is still more work to be done, we are hopeful that, together with the Senate, we will finally have the access to affordable insulin the entire T1D community deserves and depends on.”
###
Issues:Price of Insulin
DeGette Statement on the Passage of the Continuing Resolution
Position: The release supports a stopgap funding bill that avoids a government shutdown, delays an OMB proposed rule on federal grantmaking, blocks funds for immigration enforcement, and restores funding to Planned Parenthood.
WASHINGTON D.C. — Today, Congresswoman Diana DeGette (CO-01) released the following statement after voting for the stopgap funding bill:
“I supported the Senate’s stopgap funding bill that passed in the House today. Not only will it avert a harmful government shutdown, but it also delays a dangerous rule proposed by Office of Management and Budget (OMB) that allows politics to influence federal grantmaking. This proposal would be devastating for the integrity of American biomedical research, which must follow science above all other considerations.
“Additionally, the funding bill blocks funds to further Trump’s cruel immigration agenda and restores funding to Planned Parenthood, an organization that provides necessary health care to patients in Colorado and across the country.”
Background:
On July 13th, Congresswoman Diana DeGette led a comment letter signed by all the Democratic members on the Energy and Commerce Health Subcommittee urging OMB to withdraw the proposed rule.
Read the July press release here.
###
House Passes DeGette’s Bill Boosting Down Syndrome Research
Position: Representatives advocate for federal research funding and strengthened NIH collaboration on Down syndrome, and support passage of H.R. 3491, the DeOndra Dixon INCLUDE Project Act.
WASHINGTON, D.C. — Today, the U.S. House of Representatives passed H.R. 3491, the DeOndra Dixon INCLUDE Project Act, which would advance innovative research into Down syndrome. Representative Diana DeGette (CO-01), who led the bill, along with Representatives Richard Hudson (NC-09), Rosa DeLauro (CT-03), Tom Cole (OK-04), and Pete Stauber (MN-08) released the following statement:
"Today’s passage of the INCLUDE Project Act shows what we can achieve when we make Down syndrome research a true bipartisan priority," said DeGette. "By advancing this critical legislation, we are showing our commitment to improving health outcomes for individuals with Down syndrome. Colorado is already leading the way as home to the Global Down Syndrome Foundation and their affiliate, the Linda Crnic Institute—the largest institute for Down syndrome research in the world. When this bill becomes law, we will be doubling down on our commitment to groundbreaking science and to the Down syndrome community."
“People with Down syndrome enrich our families and communities in so many ways,” said Hudson. “I’m proud the House passed my bill to support research that can help them live longer, healthier lives and reach their full potential without barriers standing in their way.”
“Biomedical research is essential,” said DeLauro. “We must do all we can to strengthen the resources that lead to lifesaving medical breakthroughs and help folks with Down syndrome live long, fulfilling lives. Since 2018, as the Ranking Member of the Labor, Health and Human Services Appropriations Subcommittee, I am proud to have worked on a bipartisan basis to provide more than $400 million in funding for the more than 200 INCLUDE Project research grant awards at the National Institutes of Health. We must fight to protect that funding, and this legislation is a needed step to ensure there are no barriers to this important research.”
“Advanced medical research has the potential to change lives – and the DeOndra Dixon INCLUDE Project Act will do just that. Specifically, this legislation will strengthen the collaboration among institutes at the NIH, advance medical breakthroughs, and support Americans with down syndrome,” said Cole. “I’d like to thank Representative DeGette for taking the lead on this legislation, as we must do all we can to improve the lives of those with down syndrome.”
“I'm pleased the House passed this bill to provide robust funding for Down syndrome research. Substantial NIH research funding is needed to benefit and enhance health and quality of life for people with Down syndrome, including my own daughter Katherine, and this bill will authorize the necessary funding," said Norton. "Thank you to Rep. DeGette for your leadership on this important issue."
“As a father of a son with Down syndrome, I understand the important role research plays in improving the lives of those with disabilities,” said Stauber. “I’m proud to help lead this effort to ensure continued investment in these life-changing discoveries. Every individual deserves a chance to thrive, and this legislation brings us one step closer to that goal.”
“I have known Diana for 30 years, and throughout that time I have witnessed her extraordinary tenacity, bipartisan leadership, and ability to turn ambitious ideas into consequential legislation, and today’s unanimous House passage of the DeOndra Dixon INCLUDE Project Act adds to her legacy,” said Michelle Sie Whitten, CEO & Co-founder of the Global Down Syndrome Foundation. “GLOBAL’s advocacy, along with our allies in Congress, helped catalyze the NIH INCLUDE Project into existence as the first NIH-wide Down syndrome research program, and it is already transforming the field—driving important breakthroughs in inflammation and immune system dysregulation, Alzheimer’s disease, sleep apnea, hearing loss, cancer, and more. We are enormously grateful to Diana and her Republican lead partner, Congressman Richard Hudson, for bringing both sides of the aisle together and moving the bill one step closer to becoming law. Diana’s leadership sends a powerful message: people with Down syndrome matter, their health matters, and their futures are worth fighting for.”
“NDSC strongly supports the INCLUDE Act and applauds the bipartisan leadership behind this important legislation,” said Jim Hudson, National Down Syndrome Congress (NDSC) Executive Director. “Continued investment in Down syndrome research is essential to improving health outcomes, expanding our understanding of co-occurring conditions, and enhancing quality of life for people with Down syndrome across the lifespan.”
“NDSS is excited to celebrate the passage of the DeOndra Dixon NIH INCLUDE Project Act by the House of Representatives," said Kandi Pickard, CEO of the National Down Syndrome Society. "We have been proud to join our partners at the GLOBAL Down Syndrome Foundation and others in supporting this important legislation, which will ensure continued investments in vital biomedical research that supports the Down syndrome community. NDSS is thankful to the bill’s bipartisan champions for their leadership, and we look forward to passage by the Senate.”
The DeOndra Dixon INCLUDE Project Act formally authorizes the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project, which was launched in June 2018 at the direction of Congress to conduct research on critical health and quality-of-life needs for individuals with Down syndrome. The project investigates conditions that affect individuals with Down syndrome and the general population, such as Alzheimer’s disease and dementia, autism, cataracts, celiac disease, congenital heart disease, and diabetes.
The bill would expand clinical trials, investigate biomedical mechanisms of trisomy 21, and address the high prevalence of co-occurring conditions like Alzheimer’s and autoimmune diseases in this population.
###
DeGette, Crow, Neguse, Pettersen Statement on Massie Amendment to the Republican Budget
Position: The release states the representatives voted for Rep. Massie's amendment to the Republican budget, which would have removed additional military aid to Israel, and argues that military aid should not go to countries that do not comply with U.S. law and values.
WASHINGTON, D.C. — Representatives Diana DeGette (D-CO), Jason Crow (D-CO), Joe Neguse (D-CO), and Brittany Pettersen (D-CO) released the following statement after voting in favor of Congressman Massie’s amendment to the Republican budget:
“Today we voted against additional taxpayer-funded military aid being given to Prime Minister Netanyahu’s government.
“We support Israel’s right to exist and defend itself. We believe that both Israelis and Palestinians have the right to safety, security, and self-determination.
“We should not be giving military aid to any country that does not comply with our own laws and values. The Netanyahu government has failed to meet these standards.
“The status quo is not tenable. We need a different path forward for America’s foreign policy rooted in values and consistent application of the law.”
###
DeGette Moves to Eradicate Hepatitis C with Bipartisan Legislation
Position: The release supports introduction of the Cure Hepatitis C Act, which would establish a national test-and-treat program to help eliminate hepatitis C in the United States.
WASHINGTON, D.C. — Today, Congresswoman Diana DeGette (CO-01), Congresswoman Mariannette Miller-Meeks (IA-01), Congressman Henry C. “Hank” Johnson (GA-04), and Congressman Don Bacon (NE-02) introduced the Cure Hepatitis C Act, which would implement a national test-and-treat program to help eliminate the hepatitis C virus (HCV) in the United States.
“Thanks to the tireless efforts of biomedical researchers and innovators, hepatitis C is curable. Yet far too many people remain undiagnosed or unable to access treatment, and dozens die from the disease every day,” said DeGette. “This is simply unacceptable. We have the tools to stop this epidemic and curb the human and financial costs of this disease going untreated. I am pleased to work with my colleagues on this legislation, which will have the greatest positive impact to public health of any bill passed this Congress.”
“As a physician, I have seen what happens when a curable disease goes untreated simply because a patient couldn't access care,” said Dr. Miller-Meeks. "Hepatitis C is beatable. We have the tools to eliminate it, and this bill puts them within reach of the Americans who need them most. This is a commonsense, fiscally responsible effort that will save lives and save taxpayer dollars. I am proud to lead it alongside my colleagues on both sides of the aisle.”
“I am asking that we work together to raise awareness about hepatitis C – a silent killer – so that others at risk can get tested and treated,” said Johnson.
"This legislation represents a rare opportunity to improve health outcomes while reducing long-term health care costs," said Tim Leshan, Chief External Relations and Advocacy Officer at Association of Schools and Programs of Public Health. "We commend Representatives Miller-Meeks, DeGette, Johnson and Bacon for their bipartisan leadership and commitment to ending hepatitis C in the United States. By investing in testing, treatment, and coordinated public health efforts today, Congress can prevent liver cancer, cirrhosis, and liver transplantation tomorrow while also strengthening our nation's public health infrastructure."
“It’s vital to the health of the American people that Congress passes the Cure Hepatitis C Act,” said Saul J. Karpen, MD, PhD, FAASLD, President of American Association for the Study of Liver Diseases. “Hepatitis C affects 4 million Americans, many of whom are not aware of their disease or the ready availability for a cure, leading to a gap for these Americans regarding their future health. This bill directly addresses these gaps with practical, rapid and effective approaches that will save lives and reduce costs. We are thankful that Representatives Mariannette Miller-Meeks (R-IA), Diana DeGette (D-CO), Congressman Henry C. “Hank” Johnson (D-GA), and Congressman Don Bacon (R-NE) seized this opportunity to move this forward on behalf of patients living with hepatitis C.”
Estimates show that between 2.4 million and 4 million Americans are infected with HCV, with between 69,000 to 100,000 new cases of infection added each year. The virus is often asymptomatic, leaving many of those infected unaware of their condition.
HCV is curable with oral medication, which makes this bill even more consequential. Using a treatment course of direct-acting antivirals, more than 95 percent of people with the infection are cured in approximately 8-12 weeks. If HCV is left untreated, it can lead to lifelong chronic health issues and even death.
Additionally, the Congressional Budget Office (CBO) projects this policy could save the country more than $6 billion over the next decade.
Read the bill text here.
###
DeGette Leads Call for Withdrawal of Proposed Rule that Threatens Biomedical Research
Position: Democratic members of the House Energy and Commerce Health Subcommittee urge OMB to withdraw a proposed rule on federal financial assistance (OMB-2026-0034), arguing it would add bureaucracy to federal grantmaking, shift award decisions toward political appointees and away from peer review, and harm biomedical research and public health.
WASHINGTON, D.C. — Today, Energy and Commerce Health Subcommittee Ranking Member Diana DeGette (CO-01), Full Committee Ranking Member Frank Pallone, Jr. (NJ-06) and all Democratic members of the Health Subcommittee urged Office of Management and Budget (OMB) Director Russell Vought to withdraw the proposed rule “Regulation for Federal Financial Assistance (OMB-2026-0034).”
In a letter sent to Director Vought, the members outlined their concerns with the proposed rule.
“The proposed rule threatens a world-leading biomedical research enterprise that has taken decades to build. It adds unnecessary bureaucracy to a federal grantmaking process that has already slowed precipitously under the Trump Administration,”the letter reads.
The OMB rule would significantly change the awarding, management, and termination of federal grants and cooperative agreements across the federal government, placing unprecedented power in the hands of political appointees and shifting it away from scientists and career professionals.
The members illustrated the impact the proposed rule would have on biomedical research, scientific discovery, and public health. As a result, the rule would mean fewer new cures and fewer Americans in need receiving care.
The letter urges Director Vought to consider Congress’ intention that grantmaking be first in service of science and public health, not the political whims of any administration. It also emphasizes that Congress designed the grantmaking process to center peer review and merit, a system the proposed rule would obliterate, if implemented.
Reps. Diana DeGette (CO-01), Frank Pallone (NJ-06), Raul Ruiz (CA-25), Debbie Dingell (MI-06), Robin Kelly (IL-02), Nanette Diaz Barragán (CA-44), Kim Schrier (WA-08), Lori Trahan (MA-03), Marc Veasey (TX-33), Lizzie Fletcher (TX-07), Alexandria Ocasio-Cortez (NY-14), Jake Auchincloss (MA-04), Troy Carter (LA-02), and Greg Landsman (OH-01), who comprise the Democratic membership of the Health Subcommittee, all signed the letter.
Read the full letter here.
###
Position: The release supports the Medicare Advantage Cost Transparency Act, which would require Medicare Advantage plans to include payment amounts, cost-sharing amounts, and health risk assessment information in encounter data submitted to CMS.
WASHINGTON, D.C. — Today, the Energy & Commerce Subcommittee on Health passed the Medicare Advantage Cost Transparency Act, a bill introduced by Congresswoman Diana DeGette (CO-01) and Congressman John Joyce (PA-13). The bill will now go to the full committee for further action.
This bill would require Medicare Advantage (MA) organizations to incorporate additional data, including cost information, in encounter data submitted to the Centers for Medicare and Medicaid Services (CMS) to facilitate Medicare payment validation and to identify improper MA practices.
“Understanding what Medicare Advantage plans actually pay for care and what they force patients to pay out of their own pockets is critical to ensuring those plans are working for Americans,” said Congresswoman DeGette. “If we want to make sure these plans are working for the seniors who rely on them, we have to see how they operate. This bill shines a light on their business practices so we can hold them accountable and protect the people Medicare is supposed to serve.”
Under this legislation, plans would be required to include the following in encounter data:
What the plan paid for an item or service furnished;
The cost sharing amount (deductibles, copay, and coinsurance) imposed for each item or service;
Information about whether an MA plan facilitated a health risk assessment for the beneficiary.
The Office of the Inspector General (OIG) has identified instances of MA plans using at-home risk assessments to add questionable enrollee diagnoses that ultimately increase risk-adjusted payment from CMS without providing services related to the additional diagnoses.
Medicare Advantage plans have been criticized for their high out-of-pocket cost for patients and the shifting provider networks.
Read the full bill text here.
###
DeGette Demands Answers as Federal Agents Target Immigrant Children’s Legal Advocates
Position: The release criticizes federal agents' unannounced attempts to access offices and client records of nonprofits providing legal services to unaccompanied immigrant children, characterizing the actions as intimidation. It also calls for immediate answers from HHS Secretary Robert F. Kennedy, Jr. regarding ORR's care of unaccompanied children and its cooperation with immigration enforcement.
DENVER, CO - Today, Congresswoman Diana DeGette (CO-01) released the following statement after federal agents from ICE’s Homeland Security Investigations and Health and Human Services (HHS) Office of Inspector General attempted to access the offices and client records of nonprofits providing legal services to vulnerable, unaccompanied immigrant children:
“Federal agents showed up unannounced at children’s legal aid organizations this week with no warrant and one clear purpose: intimidation.
“It is no coincidence this happened the same week that Trump and his GOP allies handed ICE and CBP an additional $70 billion payout. These nonprofit organizations help kids prepare for court, stay safe from trafficking, and navigate a system designed for adults. They are not threats. They are a lifeline, and their young clients are often under the direct care of HHS’s Office of Refugee Resettlement (ORR).
“ORR has the responsibility for the care and placement of unaccompanied children in federal custody. Secretary Kennedy has a lot to answer for, and as the Ranking Member of the Health Subcommittee, I want answers immediately."
Background:
Earlier this week, prior to today’s reporting, Ranking Member DeGette sent a letter to Energy and Commerce Committee Chair Brett Guthrie and Health Subcommittee Chair Morgan Griffith requesting a hearing with the Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., Assistant Secretary for Administration for Children and Families Alex J. Adams and ORR Acting Director Angie Salazar.
HHS is statutorily required to provide services and care for these children under the Unaccompanied Children Program. However, reports show that ORR has taken actions over the past 17 months that jeopardize the well-being of unaccompanied children and undermine the program, including allegations of extended detention periods of 200+ days and increased cooperation with immigration enforcement agencies that harm placement and sponsor vetting.
###
DeGette Leads Over 250 Congressional Democrats on Amicus Brief to Supreme Court in Louisiana v. FDA
Position: Rep. DeGette and over 250 Congressional Democrats argue that the FDA's authority to regulate medication abortion should be upheld, that mifepristone has been proven safe and effective, and that courts should not override FDA determinations on drug safety and efficacy.
DENVER, CO — Today, Congresswoman Diana DeGette (CO-01), co-chair of the Reproductive Freedom Caucus, is leading more than 250 Congressional Democrats in filing an amicus brief to the U.S. Supreme Court in State of Louisiana v. U.S. Food and Drug Administration (FDA), a case that could have sweeping implications for access to medication abortion nationwide.
“This case is about whether science and evidence still guide our nation’s health decisions, as Congress codified in law, or whether state politicians and courts can override them,” said Rep. DeGette. “Mifepristone has been proven safe and effective for more than 25 years. Reinstating medically unnecessary restrictions will only make it harder for Americans to access care, especially those in rural and underserved communities. I’m proud to lead my colleagues in standing up for patients, for science, and for the FDA’s authority.”
Louisiana v. FDA stems from ongoing legal challenges by anti-abortion politicians and advocates seeking to restrict access to medication abortion. On May 1, the Fifth Circuit Court of Appeals granted Louisiana’s request for a nationwide judgment requiring patients to fill mifepristone prescriptions in person at a health center, effectively ending access via telehealth, mail order, and pharmacy. On May 4, the Supreme Court granted an administrative stay in Louisiana v. FDA. This restores access to mifepristone via telehealth, mail order, and pharmacies for one week while the case proceeds on emergency docket.
Medication abortion care accounts for nearly two-thirds of all abortions in the U.S., and more than one in four abortion patients in the United States receive their safe, effective care via telehealth. The Fifth Circuit’s ruling would significantly restrict access—even in states where abortion remains legal—by imposing barriers that medical experts say are medically unnecessary and unduly burdensome.
Mifepristone, part of the gold standard medication abortion regimen, was approved by the FDA more than 25 years ago and has since been used safely by over 7.5 million patients. The FDA’s decision to remove the in-person dispensing requirement was based on extensive scientific evidence demonstrating the medication’s safety and efficacy.
Congressional Democrats argue in their amicus brief that allowing courts to override FDA determinations undermines the agency’s authority as established by Congress and threatens the integrity of the nation’s drug approval process.
###
Issues:Restoring Reproductive Rights
Source: GDELT 2.0 GKG, filtered to a curated list of national outlets. Inclusion is not endorsement; opinion pieces and reported news are mixed.
Recent stock activity
Periodic transaction reports filed under the STOCK Act — disclosed by the rep, sourced from public filings.
No disclosed trades on record.
Source: open-data mirrors of the Senate eFD and House Clerk financial-disclosure systems. Disclosure within 30 days of trade is required by law (45 for spouse/dependent trades).
Top PAC donors · 2026 cycle
Political action committees that gave the most to this rep's principal campaign committee this cycle. PAC giving is direct organizational support — industry, ideological, or leadership.
1.SHEET METAL WORKERS INTERNATIONAL ASSOCIATION POLITICAL ACTION LEAGUE2 contributions$10,000
9.BALL CORPORATION POLITICAL ACTION COMMITTEE2 contributions$10,000
10.AMERIPAC2 contributions$10,000
Source: OpenFEC (api.open.fec.gov) Schedule A receipts where contributor type is “committee.” Aggregated by contributing committee. Self-transfers from joint-fundraising / victory committees are excluded.
Top individual contributors · 2026 cycle
Itemized individual contributions over $200 to this rep's campaign committee, aggregated by donor employer. PAC giving is shown above; this section is people, not organizations.
1.SELF$70,601
2.ANTHROPIC$14,000
3.RED+BLUE STRATEGIES$7,500
4.PISCES, INC.$7,000
5.MURPHY CONSTRUCTION$7,000
6.PARTNER AT KLEINER PERKINS CAUFIELD &$7,000
7.MONROE GROUP$7,000
8.INSIGHT VENTURE PARTNERS$7,000
9.CALIBRATED MARKETS LLC$7,000
10.MANZANITA CAPITAL$7,000
Source: OpenFEC Schedule A receipts where contributor type is “individual,” aggregated by the donor's self-reported employer. This is a geographic / industry correlation, not a corporate endorsement.
